Cellectar Biosciences, Inc.
CLRB
We are a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Our core objective is to leverage our proprietary phospholipid ether drug conjugate (PDC ) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$26M
▲ +51.1% YoY
Op. Margin
–
ROIC
-122.38%
▲ +380.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$25M
▲ +51.5% YoY
Op. Cash Flow (TTM)
-$25M
▲ +51.4% YoY
Net Debt
-$23M
Net Cash Position
Cash & Equiv.
$25M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with CLRB
Cellectar Biosciences (CLRB) in two numbers
Questions about Cellectar Biosciences
Does Cellectar Biosciences (CLRB) pay a dividend?
No. Cellectar Biosciences (CLRB) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 6 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in CLRB's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing CLRB
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.